Table 3 Multiple variables Cox regression to estimate the hazard ratio (HR) in subgroup analysis

Study

 Non-SGLT2i

Reference

Reference

 SGLT2i

0.95(0.87–1.05)

0.96(0.86–1.07)

SGLT2i subtype(ref: non)

 Dapagliflozin

0.99(0.89–1.12)

0.99(0.87–1.13)

 Canagliflozin

0.58(0.19–1.82)

0.63(0.20–1.97)

 Empagliflozin

0.91(0.80–1.03)

0.91(0.79–1.05)

Type 2 DM history

  <  = 2 years

1.46(1.23–1.73)

1.53(1.24–1.9)

 3–4 years

1.17(1.04–1.32)

1.16(0.99–1.35)

  >  = 5 years

Reference

Reference

Sex

 Female

Reference

Reference

 Male

1.47(1.34–1.60)

1.41(1.26–1.58)

 Female (users vs. non-users)

0.88(0.78–1.00)

0.90(0.79–1.02)

 Male (users vs. non-users)

0.99(0.87–1.13)

0.98(0.86–1.11)

Age

 65–69

Reference

Reference

 70–79

1.33(1.21–1.47)

1.34(1.19–1.51)

 80 up

1.89(1.66–2.15)

2.00(1.70–2.36)